Sentinel Cohort Launched as Oral Vaccine Advances Towards FDA and BARDA Support
Vaxart Inc. (VXRT) has announced the initiation of the sentinel cohort for its Phase 2b study evaluating its oral COVID-19 vaccine. This development marks a significant step forward in Vaxart’s ongoing mission to offer a unique, convenient alternative to injectable vaccines. The trial, which compares Vaxart’s oral vaccine against an approved mRNA vaccine, signals the company’s commitment to addressing unmet needs in COVID-19 prevention, particularly as new variants continue to emerge.
Vaxart’s approach has already garnered substantial interest and support. The Biomedical Advanced Research and Development Authority (BARDA) awarded the company a grant worth up to $453 million to conduct the trial, highlighting the potential impact of this innovative oral vaccine. With the sentinel cohort now underway, expectations are high that this novel solution could offer key advantages in the fight against COVID-19.
Launching the Phase 2b Study
The Phase 2b clinical trial has begun with a sentinel cohort of 400 participants, who will be randomized 1:1 to receive either Vaxart’s oral COVID-19 vaccine or an FDA-approved mRNA vaccine. This cohort serves as the first step in a larger trial involving 10,000 subjects across the U.S. The goal of this study is to assess the safety and efficacy of Vaxart’s oral vaccine and to compare its performance with the widely used mRNA vaccines currently on the market.
Following a 30-day safety review by an independent data and safety monitoring board and the FDA, the study could move forward with the remaining 9,600 participants. If the sentinel cohort demonstrates favorable safety outcomes, it will provide a strong foundation for advancing the trial and moving closer to potential regulatory approval.
Differentiating Features of Vaxart’s Oral Vaccine
Vaxart’s oral COVID-19 vaccine stands out from traditional intramuscular vaccines due to its unique delivery method and promising early results. The vaccine has shown potential to boost immunity when used alongside mRNA vaccines, particularly in stimulating mucosal immunity, which is critical in preventing respiratory infections like COVID-19. Additionally, preclinical studies suggest that the oral vaccine may offer cross-reactive protection against various strains of the virus, addressing concerns about emerging variants.
One of the key benefits of an oral vaccine is its ease of administration, which could improve vaccination rates, especially in populations with limited access to healthcare facilities. Oral vaccines also eliminate the need for cold chain storage, making them easier to distribute in global settings, particularly in lower-income countries where vaccine logistics have been a challenge.
Management’s Optimism and Future Plans
Vaxart’s management has expressed confidence in the company’s ability to execute the clinical trial in alignment with BARDA and the FDA. The timely initiation of the sentinel cohort is seen as a reflection of the company’s dedication to advancing the program and meeting the unmet needs in COVID-19 prevention. Strong interest in an oral COVID-19 vaccine further bolsters management’s confidence in the program’s potential.
Moreover, Vaxart’s 10-K filing indicates that BARDA has approved additional funding for the company to begin manufacturing an oral vaccine candidate targeting the KP.2 strain, demonstrating the government’s ongoing support for Vaxart’s innovative approach.
A Promising Pipeline Beyond COVID-19
While Vaxart’s COVID-19 vaccine program garners much attention, the company is also advancing its oral norovirus vaccine, another key asset in its portfolio. Both the norovirus and COVID-19 vaccines are built on Vaxart’s differentiated oral vaccine platform, which offers a novel solution to global healthcare challenges.
The global market for COVID-19 vaccines remains significant, especially as new variants emerge and booster doses are required. Norovirus, a highly contagious virus causing gastroenteritis, also represents an attractive market with no approved vaccines currently available. Vaxart’s oral vaccines, if successful, could tap into these large unmet needs, positioning the company as a key player in both areas.
Looking Ahead
The initiation of the Phase 2b trial for Vaxart’s oral COVID-19 vaccine marks a critical milestone for the company. As the trial progresses and safety data from the sentinel cohort become available, Vaxart is poised to make significant strides in its quest to offer a convenient, effective alternative to traditional vaccines. With the ongoing support of BARDA and the FDA, Vaxart’s oral vaccine platform holds the potential to reshape the landscape of COVID-19 prevention and beyond.
For investors, Vaxart’s recent achievements, coupled with its upcoming clinical and regulatory milestones, present a compelling case for the company’s future growth. As the trial unfolds and more data become available, Vaxart’s innovative approach may offer a breakthrough in global vaccination efforts, especially in hard-to-reach populations and in combatting new viral variants.
You might like this article:Dallas Homebuilders Face Mixed Signals Amid Market Challenges
